PRESS RELEASE 2011

Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (PENTASA®) in active ulcerative colitis

Results of a new study presented today at the United European Gastroenterology Week (UEGW) congress in Stockholm demonstrate…

Ferring Pharmaceuticals acquires Cytokine PharmaSciences Inc.

Ferring Pharmaceuticals (Ferring) announced today that it has completed the purchase of Cytokine PharmaSciences Inc. (CPSI) and its…

The untold impact of childhood bedwetting in later life

New data, presented today at the International Continence Society (ICS) congress in Glasgow, suggest that bedwetting…

New research reveals night-time toilet trips are not a trivial problem

New data, presented at the International Continence Society (ICS) Congress, highlight the significant detrimental impact of nocturia…

New data demonstrating long-term benefits of FIRMAGON® (degarelix) for advanced hormone-dependant prostate cancer published in The Journal of Urology

New data, published in the September issue of The Journal of Urology, showed that long-term use of FIRMAGON®…

MEGASET Study demonstrated effectiveness and tolerability of MENOPUR® after ICSI in GnRH antagonist cycles

New data presented today at the European Society of Human Reproduction and Embryology (ESHRE) meeting, demonstrated the efficacy…

Ongoing extension study results provide further evidence for first-line use of FIRMAGON® (degarelix) in advanced prostate cancer

Recent data from the ongoing five-year FIRMAGON® (degarelix) extension study (CS21a) has demonstrated the long term efficacy and tolerability of…

SMC Announces Acceptance of Degarelix (FIRMAGON®▼) for use within NHS Scotland

Today’s decision by the Scottish Medicines Consortium (SMC) to accept the use of FIRMAGON…